Charles Schwab Investment Management Inc. Boosts Stock Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 8.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 233,717 shares of the company’s stock after acquiring an additional 17,372 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Ginkgo Bioworks were worth $2,295,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. SBI Securities Co. Ltd. bought a new stake in Ginkgo Bioworks in the 4th quarter worth approximately $29,000. SVB Wealth LLC bought a new position in shares of Ginkgo Bioworks during the fourth quarter valued at approximately $171,000. Bank of New York Mellon Corp raised its holdings in shares of Ginkgo Bioworks by 48.2% during the fourth quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company’s stock valued at $226,000 after acquiring an additional 7,503 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Ginkgo Bioworks in the fourth quarter valued at $154,000. Finally, Palumbo Wealth Management LLC bought a new stake in shares of Ginkgo Bioworks during the 4th quarter valued at about $144,000. Institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Performance

DNA stock opened at $6.16 on Friday. The company has a market capitalization of $357.26 million, a price-to-earnings ratio of -0.47 and a beta of 1.23. The business’s 50 day moving average price is $10.36 and its two-hundred day moving average price is $9.22. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $47.60.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.